Eli Lilly and Company [NYSE: LLY] traded at a low on 04/26/23, posting a -2.23 loss after which it closed the day’ session at $376.27. The company report on April 24, 2023 at 6:45 AM that Lilly to Divest BAQSIMI to Amphastar.
Lilly focused on delivering the company’s unprecedented pipeline of next-generation medicines to help patients.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Amphastar is the ideal company to continue Lilly’s mission to help more people benefit from BAQSIMI.
The results of the trading session contributed to over 3135863 shares changing hands. Over the past one week, the price volatility of Eli Lilly and Company stands at 1.98% while the volatility over the past one month is 1.66%.
The market cap for LLY stock reached $348.64 billion, with 952.35 million shares outstanding and 950.54 million shares in the current float. Compared to the average trading volume of 3.22M shares, LLY reached a trading volume of 3135863 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Eli Lilly and Company [LLY]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LLY shares is $383.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LLY stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Eli Lilly and Company shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 13, 2023. While these analysts kept the previous recommendation, Jefferies raised their target price to Hold. The new note on the price target was released on March 06, 2023, representing the official price target for Eli Lilly and Company stock.
The Average True Range (ATR) for Eli Lilly and Company is set at 7.27, with the Price to Sales ratio for LLY stock in the period of the last 12 months amounting to 12.22. The Price to Book ratio for the last quarter was 31.86, with the Price to Cash per share for the same quarter was set at 2.39. Price to Free Cash Flow for LLY in the course of the last twelve months was 205.77 with Quick ratio for the last quarter at 0.80.
How has LLY stock performed recently?
Eli Lilly and Company [LLY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.57. With this latest performance, LLY shares gained by 12.45% in over the last four-week period, additionally plugging by 8.15% over the last 6 months – not to mention a rise of 31.93% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LLY stock in for the last two-week period is set at 64.34, with the RSI for the last a single of trading hit 60.65, and the three-weeks RSI is set at 63.97 for Eli Lilly and Company [LLY]. The present Moving Average for the last 50 days of trading for this stock 341.84, while it was recorded at 380.90 for the last single week of trading, and 339.28 for the last 200 days.
Eli Lilly and Company [LLY]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Eli Lilly and Company [LLY] shares currently have an operating margin of +29.01 and a Gross Margin at +76.77. Eli Lilly and Company’s Net Margin is presently recorded at +21.88.
Return on Total Capital for LLY is now 31.22, given the latest momentum, and Return on Invested Capital for the company is 25.12. Return on Equity for this stock inclined to 63.63, with Return on Assets sitting at 12.71. When it comes to the capital structure of this company, Eli Lilly and Company [LLY] has a Total Debt to Total Equity ratio set at 152.48. Additionally, LLY Total Debt to Total Capital is recorded at 60.39, with Total Debt to Total Assets ending up at 32.81. Long-Term Debt to Equity for the company is recorded at 138.38, with the Long-Term Debt to Total Capital now at 54.81.
Reflecting on the efficiency of the workforce at the company, Eli Lilly and Company [LLY] managed to generate an average of $160,123 per employee. Receivables Turnover for the company is 3.42 with a Total Asset Turnover recorded at a value of 0.58.Eli Lilly and Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.10.
Earnings analysis for Eli Lilly and Company [LLY]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LLY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Eli Lilly and Company go to 22.57%.
Insider trade positions for Eli Lilly and Company [LLY]
There are presently around $297,173 million, or 84.80% of LLY stock, in the hands of institutional investors. The top three institutional holders of LLY stocks are: LILLY ENDOWMENT INC with ownership of 102,543,810, which is approximately -0.393% of the company’s market cap and around 10.90% of the total institutional ownership; VANGUARD GROUP INC, holding 73,429,863 shares of the stock with an approximate value of $27.63 billion in LLY stocks shares; and BLACKROCK INC., currently with $24.49 billion in LLY stock with ownership of nearly 1.502% of the company’s market capitalization.
Positions in Eli Lilly and Company stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 1,244 institutional holders increased their position in Eli Lilly and Company [NYSE:LLY] by around 23,429,442 shares. Additionally, 1,172 investors decreased positions by around 58,812,402 shares, while 378 investors held positions by with 707,545,054 shares. The mentioned changes placed institutional holdings at 789,786,898 shares, according to the latest SEC report filing. LLY stock had 254 new institutional investments in for a total of 4,028,566 shares, while 133 institutional investors sold positions of 22,600,499 shares during the same period.